FDA Approves MYCOPHENOLIC ACID — Archis Pharma LLC

On January 8, 2014, Archis Pharma LLC received FDA approval for its ANDA 091248, launching oral mycophenolic acid to provide a new therapeutic option for transplant immunosuppression. The approval allows the company to compete with market leaders by offering this essential drug at a more accessible price point, potentially impacting pricing strategies in the graft-versus-host disease and organ transplant sectors.